Episode 10 July (post quiz)

Episode 10 - July (post quiz)

Which biomarker is most often used to guide first-line immunotherapy decisions in advanced NSCLC?(Required)
What is a preferred first-line treatment for PD-L1 ≥50% advanced NSCLC with no actionable mutations?(Required)
Why are immunotherapies often avoided in patients with EGFR or ALK alterations?(Required)